Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020:1258:141-155.
doi: 10.1007/978-3-030-43085-6_9.

Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update

Edward M Greenfield  1 , Christopher D Collier  2 , Patrick J Getty  3   4
Affiliations
Free article
Review

Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update

Edward M Greenfield et al. Adv Exp Med Biol. 2020.
Free article

Abstract

The primary conclusions of our 2014 contribution to this series were as follows: Multiple receptor tyrosine kinases (RTKs) likely contribute to aggressive phenotypes in osteosarcoma and, therefore, inhibition of multiple RTKs is likely necessary for successful clinical outcomes. Inhibition of multiple RTKs may also be useful to overcome resistance to inhibitors of individual RTKs as well as resistance to conventional chemotherapies. Different combinations of RTKs are likely important in individual patients. AXL, EPHB2, FGFR2, IGF1R, and RET were identified as promising therapeutic targets by our in vitro phosphoproteomic/siRNA screen of 42 RTKs in the highly metastatic LM7 and 143B human osteosarcoma cell lines. This chapter is intended to provide an update on these topics as well as the large number of osteosarcoma clinical studies of inhibitors of multiple tyrosine kinases (multi-TKIs) that were recently published.

Keywords: AXL; EPHB2; FGFR2; IGF1R; Multi-TKIs; Osteosarcoma; RET; Receptor tyrosine kinases.

PubMed Disclaimer